Literature DB >> 11236071

Atypical antipsychotics and hyperglycaemia.

S Mir1, D Taylor.   

Abstract

Hyperglycaemia is known occasionally to occur with conventional neuroleptics, but has more recently been associated with atypical antipsychotics especially clozapine and olanzapine. This article examines more closely this association. A review of relevant published literature from 1970 to date was undertaken following Medline and Embase searches in June 2000. Hyperglycaemia with clozapine was widely reported: spontaneous reports of either hyperglycaemia or ketoacidosis were described in a total of 17 people. In a five-year naturalistic study, 30.5% of patients taking clozapine were eventually diagnosed with Type 2 diabetes. With olanzapine, a total of 10 cases of hyperglycaemia and 5 cases of ketoacidosis have been published. Reports of hyperglycaemia with other atypicals are relatively scarce. The association of hyperglycaemia or ketoacidosis with clozapine and olanzapine appears to be a true drug-induced effect. Risk factors may include male gender, age of around 40 years and being non-Caucasian. The management of hyperglycaemia depends on the causative agent. With clozapine, treatment with oral hypoglycaemics has been successful. With olanzapine, other atypical antipsychotics may be considered. Blood glucose monitoring is essential for all patients starting clozapine or olanzapine.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11236071     DOI: 10.1097/00004850-200103000-00001

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  13 in total

Review 1.  Understanding antipsychotic "atypicality": a clinical and pharmacological moving target.

Authors:  Gary Remington
Journal:  J Psychiatry Neurosci       Date:  2003-07       Impact factor: 6.186

Review 2.  Metabolic consequences of atypical antipsychotic drugs.

Authors:  Harold E Lebovitz
Journal:  Psychiatr Q       Date:  2003

Review 3.  Pharmacogenetics of antipsychotic-induced weight gain.

Authors:  Christoph U Correll; Anil K Malhotra
Journal:  Psychopharmacology (Berl)       Date:  2004-07-08       Impact factor: 4.530

Review 4.  Cardiovascular Disease in Clozapine-Treated Patients: Evidence, Mechanisms and Management.

Authors:  Kathlyn J Ronaldson
Journal:  CNS Drugs       Date:  2017-09       Impact factor: 5.749

5.  Glucose intolerance with atypical antipsychotics.

Authors:  Karin Hedenmalm; Staffan Hägg; Malin Ståhl; Orjan Mortimer; Olav Spigset
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 6.  Prevention of schizophrenia: can it be achieved?

Authors:  Cheng Lee; Thomas H McGlashan; Scott W Woods
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

7.  A UK audit of screening for the metabolic side effects of antipsychotics in community patients.

Authors:  Thomas R E Barnes; Carol Paton; Mary-Rose Cavanagh; Elizabeth Hancock; David M Taylor
Journal:  Schizophr Bull       Date:  2007-05-04       Impact factor: 9.306

Review 8.  Ziprasidone in the management of schizophrenia : the QT interval issue in context.

Authors:  David Taylor
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

9.  Conventional and atypical antipsychotics in the elderly : a review.

Authors:  Pietro Gareri; Pasquale De Fazio; Mariagrazia Stilo; Guido Ferreri; Giovambattista De Sarro
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

10.  Metabolic Issues With Atypical Antipsychotics in Primary Care: Dispelling the Myths.

Authors:  Gary S. Kabinoff; Patrick A. Toalson; Kristine Masur Healey; Hillary C. McGuire; Donald P. Hay
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2003-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.